Cytel is the world’s leading data-science CRO, driving advancements in human health through robust analytics and innovative clinical trial software. For nearly four decades, we have set the standard in adaptive trial design, leveraging extensive data insights to inform strategy throughout every phase of drug development and commercialization. Our mission is clear: accelerate drug development, enhance success rates, and deliver better patient outcomes. With a comprehensive suite of services from innovative trial design to end-to-end biometrics and real-world evidence, our specialized, multidisciplinary team ensures optimal strategies for preclinical research, trial execution, market access, and reimbursement. Headquartered in Cambridge, Massachusetts, Cytel has a global presence with over 2,000 employees across North America, Europe, and Asia. Learn more about how Cytel is harnessing the power of data to advance human health at www.cytel.com.
External link for Cytel
It's again time for our Fun Friday Facts! 🎉 Today we're diving deeper into some of our data facts! More specifically all the different trials we've been involved in! 👨🔬 As always, want to read up before you answer? Check out our new website www.cytel.com
This content isn’t available here
Access this content and more in the LinkedIn app
🚀 Exciting News from Cytel! 🚀 We are excited to announce the launch of our new Evidence, Value, and Access Methods Innovation Hub! At Cytel, our mission is to drive innovation by developing advanced analytical solutions. This new hub is dedicated to tackling key regulatory, reimbursement, and access challenges faced by manufacturers. By leveraging our advanced analytical solutions and collaborating with industry experts, we remain at the forefront of life sciences policy developments, ensuring we capture the optimal value of your product! Stay updated with our latest developments by following us on LinkedIn
Recently, we launched our redesigned website and refreshed brand, showcasing not just a new look, but a renewed commitment to driving success in drug development and commercialization, and improving patient outcomes. ✍️ In our latest blog, Sofie Vandevyver, PhD, Vice President and Global Head of Marketing at Cytel, explains the reasons behind our transformation and the core elements of our new brand. And that's not all! 💡Sofie dives into the hottest industry trends and reveals how we are uniquely positioned to help you unlock the full potential of therapies. Read the full article: https://bit.ly/4cxJIaE #DataScience #DrugDevelopment #NewCytel #Transformation #PatientOutcomes
🎉 Kudos as well to our colleagues Andreas Freitag, Grammati Sarri, An Ta Kakouriotis, and Laura Gurskyte for their publication! 🌟 Our paper highlights that conventional approaches (e.g., PSM or Markov models) continue to be most commonly used for health economic models in #RRMM, most likely driven by lower data requirements and established precedents across prior #HTA submissions. However, the identified models rarely addressed the evolving treatment landscape in RRMM; as more patients experience disease progression there is a growing need to model longer and more diverse treatment sequences more accurately. For this reason and together with recent HTA guidance on the limitations of PSMs, future models will require the use of more complex and sophisticated modelling approaches. Our review also highlights the importance of increased transparency and comprehensiveness of reporting, particularly around model validation and uncertainty analysis. Read the full publication here: https://lnkd.in/gphHAHUF
🔍 Unlocking Insights: German Claims Data & EMR Linkage 🔍 💡 Harnessing the synergy between German claims data and electronic medical records (EMR) opens new avenues for healthcare research. 💡 In a recent linked-data study, colleagues Marco Ghiani and Evi Zhuleku helped develop a German claims-based algorithm for deriving the Expanded Disability Status Scale (EDSS) in people with multiple sclerosis (MS) and validated the proxy against clinical data. Leveraging linked German claims data and EMRs from the Multiple Sclerosis Management System 3D (MSDS3D), the algorithm showed promise, particularly in broader severity groupings, despite underestimating mild-to-moderate symptoms. This use case highlights the potential of German claims data and EMR linkage for developing proxies to assess MS disability, offering insights into disease progression and treatment effectiveness. By harnessing the strengths of multiple real-world data sources, linked-data studies can increase the utility of real-world evidence. Link to article: https://bit.ly/4cQXCo4
Two more days until our webinar "Project Optimus: Dose Escalation and Stratification Designs in Early Oncology Development" with James Matcham and Mike Fossler! Click here to register: https://hubs.ly/Q02BSNR00 #OncologyTrials #BasketTrials #Bayesian
52% guessed last weeks Fun Facts Friday's answer correctly! 🎉 Cytel was founded in 1987 by Cyrus Mehta and Nitin Patel! Do you want to learn more about our 37 year history? Discover more on our new website: https://lnkd.in/emCGuxA2 #Cytel #Biostatistics
With our new brand we're also starting Fun Facts Friday on LinkedIn! 🎉 Every Friday, we will divulge a new fact on Cytel via a poll, and every Monday, we will post the correct response via a blog! Looking for the answer? 🔎 It helps to browse our new website https://bit.ly/3xAdgFD We're starting off easy this week (for those that know Cytel 😉)
This content isn’t available here
Access this content and more in the LinkedIn app
Smiles all around during our latest Cytel Statistical Innovator Forums this week in Shanghai and Beijing! It’s great to bring together many biostatisticians to discuss and share their experience with Cytel’s solutions. A big thank you to all our guest speakers and Cytel's guest consultant Yuan J., Professor of Biostatistics at the University of Chicago! Special thanks to the entire Cytel team: Yannis Jemiai, Christy Fang, Handong Li, Lee Xu, Jiaxin Liu, Emma Han, Shen Yang #Biostatistics #Innovation #EastHorizon